 The study found that Illinois 17i treatment did not increase the risk of COVID-19 infection, hospitalization, or mortality in patients with psoriasis, and therefore supports its continued use during the pandemic. This article was authored by Calif Cryding, Noki Shonman, Ori Solomon, and others.